<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412982</url>
  </required_header>
  <id_info>
    <org_study_id>Droege2015</org_study_id>
    <nct_id>NCT02412982</nct_id>
  </id_info>
  <brief_title>Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients</brief_title>
  <official_title>Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients: A Prospective Randomized Trial of Standard Enoxaparin Versus Two Anti-Xa Adjusted Dosing Strategies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Air Force</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ&#xD;
      between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed&#xD;
      on enoxaparin 30 mg twice daily for VTE prophylaxis. Secondarily, this study will compare two&#xD;
      enoxaparin dosing strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study to determine if AT-III serum concentrations differ between patients&#xD;
      with normal (&gt;= 0.1 IU/mL) versus subtherapeutic (&lt;0.1 IU/mL) anti-Xa trough concentrations&#xD;
      when placed on enoxaparin 30 mg twice daily for venous thromboembolism (VTE) prophylaxis.&#xD;
      Secondarily, this study will compare two enoxaparin dosing strategies: standard 30 mg twice&#xD;
      daily and a dosing strategy based on trough anti-Xa values in high-risk trauma patients.&#xD;
&#xD;
      Specific aims include: 1) to compare the extent of reduced AT-III activity between patients&#xD;
      with trough anti-Xa &gt;= 0.1 IU/mL and &lt; 0.1 IU/mL upon initial assay; 2) to determine the&#xD;
      proportion of patients who reach goal anti-Xa and the time to goal anti-Xa achievement&#xD;
      between two interventional dosing strategies: enoxaparin 40 mg every 12 hours (with&#xD;
      consideration to increase to 50 mg every 12 hours if recheck anti-Xa is not at goal) and&#xD;
      enoxaparin 30 mg every eight hours; 3) to compare anti-Xa enoxaparin dosing strategies based&#xD;
      on VTE, bleeding rates, transfusion requirements, drug discontinuation rate and&#xD;
      bioaccumulation, and 4) to determine patient-specific factors that correlate to&#xD;
      subtherapeutic anti-Xa such as serial AT-III activity, weight, body mass index, age,&#xD;
      cumulative fluid administration, and thromboelastography (TEG).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial AT-III Activity -- Control Group vs. Intervention Group Prior to Randomization</measure>
    <time_frame>After third dose of enoxaparin 30mg q12h, which will typically be on Day 2 of enoxaparin</time_frame>
    <description>Serum AT-III (% activity) will be compared between the control group and the intervention group patients (combined) after the third dose of enoxaparin 30 mg every 12 hours once initiated at the discretion of the trauma service per current VTE prophylaxis protocol</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Traumatic Injury</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Serum anti-Xa &gt;= 0.1 IU/mL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with serum anti-Xa level &gt;= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-Xa &lt;0.1 IU/mL:enoxaparin 40 mg q12h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with serum anti-Xa level &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-Xa &lt;0.1 IU/mL:enoxaparin 30 mg q8h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with serum anti-Xa level &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serum anti-Xa &lt; 0.1 IU/mL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with serum anti-Xa level &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 40 mg q12h</intervention_name>
    <description>Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.</description>
    <arm_group_label>Anti-Xa &lt;0.1 IU/mL:enoxaparin 40 mg q12h</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 30 mg q8h</intervention_name>
    <description>Patients receive enoxaparin 30 mg every 8 hours.</description>
    <arm_group_label>Anti-Xa &lt;0.1 IU/mL:enoxaparin 30 mg q8h</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multi-system trauma&#xD;
&#xD;
          -  Anticipated length of stay of at least 72 hours&#xD;
&#xD;
          -  At high risk (risk adjustment profile [RAP] &gt;= 5) and initiated on enoxaparin 30 mg&#xD;
             every 12 hours per VTE prophylaxis protocol&#xD;
&#xD;
          -  No counterindication to trauma team VTE prophylaxis protocol (e.g., intracranial&#xD;
             bleeding, incomplete spinal cord injury with hematoma within 24 hours post injury,&#xD;
             ongoing hemorrhage, uncorrected coagulopathy, &gt;= grade IV liver or spleen injury,&#xD;
             intraocular injury)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal dysfunction (creatinine clearance &lt; 30 mL/min or on continuous renal replacement&#xD;
             therapy)&#xD;
&#xD;
          -  Weight &lt; 50 kg or &gt; 150 kg&#xD;
&#xD;
          -  Platelet count &lt; 50,000&#xD;
&#xD;
          -  Allergy to heparin or low molecular weight heparin&#xD;
&#xD;
          -  On therapeutic anticoagulation on admission or requiring it within 24 hours of&#xD;
             admission&#xD;
&#xD;
          -  Isolated intracranial hemorrhage&#xD;
&#xD;
          -  Known hyperbilirubinemia (serum bilirubin &gt; 6.6 mg/dL)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Incarceration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Molly Droege, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Health - University of Cincinnati Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Droege ME, Droege CA, Philpott CD, Webb ML, Ernst NE, Athota K, Wakefield D, Dowd JR, Gomaa D, Robinson BHR, Hanseman D, Elterman J, Mueller EW. Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial. J Thromb Thrombolysis. 2021 May 12. doi: 10.1007/s11239-021-02478-4. [Epub ahead of print]</citation>
    <PMID>33978907</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>June 30, 2021</results_first_submitted>
  <results_first_submitted_qc>October 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2021</results_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Molly Droege</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist, Trauma, Surgery, and Orthopedics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Enoxaparin sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02412982/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1496 screened for eligibility. 1393 excluded.&#xD;
51 in control group (anti-Xa 0.1 IU/mL or greater); 52 in intervention group (anti-Xa &lt; 0.1 IU/mL)&#xD;
52 patients in the intervention group underwent 1:1 randomization to the two intervention study arms: 26 patients in 40 mg every 12 hours with escalation to 50 mg every 12 hours and 26 patients in 30 mg every 8 hours.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Patients with serum anti-Xa level &gt;= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours&#xD;
n = 51 4 with AT-III not collected so 47 included in primary outcome analysis</description>
        </group>
        <group group_id="P2">
          <title>Intervention Group</title>
          <description>Patients with serum anti-Xa &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours&#xD;
n = 52&#xD;
1 patient withdrew consent; 2 patients did not have AT-III collected. 49 total included in primary outcome analyses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Endpoint</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention Group: Randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Control group patients did not undergo randomization (see study protocol section)</participants>
                <participants group_id="P2" count="52">52 patients in the intervention group underwent 1:1 randomization to the two intervention study arms: 26 patients in 40 mg every 12 hours with escalation to 50 mg every 12 hours and 26 patients in 30 mg every 8 hours.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control: Serum Anti-Xa &gt;= 0.1 IU/mL</title>
          <description>Patients with serum anti-Xa level &gt;= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours</description>
        </group>
        <group group_id="B2">
          <title>Intervention: Serum Anti-Xa &lt; 0.1 IU/mL</title>
          <description>Patients with serum anti-Xa level &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="25" upper_limit="58"/>
                    <measurement group_id="B2" value="41" lower_limit="26" upper_limit="56"/>
                    <measurement group_id="B3" value="41" lower_limit="26" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Initial AT-III Activity -- Control Group vs. Intervention Group Prior to Randomization</title>
        <description>Serum AT-III (% activity) will be compared between the control group and the intervention group patients (combined) after the third dose of enoxaparin 30 mg every 12 hours once initiated at the discretion of the trauma service per current VTE prophylaxis protocol</description>
        <time_frame>After third dose of enoxaparin 30mg q12h, which will typically be on Day 2 of enoxaparin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients with serum anti-Xa level &gt;= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours&#xD;
n = 51 4 with AT-III not collected so 47 included in primary outcome analysis</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Patients with serum anti-Xa &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours&#xD;
n = 52&#xD;
1 patient withdrew consent; 2 patients did not have AT-III collected. 49 total included in primary outcome analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Initial AT-III Activity -- Control Group vs. Intervention Group Prior to Randomization</title>
          <description>Serum AT-III (% activity) will be compared between the control group and the intervention group patients (combined) after the third dose of enoxaparin 30 mg every 12 hours once initiated at the discretion of the trauma service per current VTE prophylaxis protocol</description>
          <units>Percent AT-III activity (%)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O2" value="82" lower_limit="71" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During patient enrollment up to 28 days, while inpatient</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Patients with serum anti-Xa level &gt;= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours&#xD;
n = 51 4 with AT-III not collected so 47 included in primary outcome analysis</description>
        </group>
        <group group_id="E2">
          <title>Intervention Group</title>
          <description>Patients with serum anti-Xa &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours&#xD;
n = 52&#xD;
1 patient withdrew consent; 2 patients did not have AT-III collected. 49 total included in primary outcome analyses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Underpowered; See full results and manuscript listed in citation section.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Molly Droege, PharmD</name_or_title>
      <organization>UC Health - University of Cincinnati Medical Center</organization>
      <phone>513-584-2126</phone>
      <email>molly.droege@uchealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

